Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW DRUGS

On September 20, 2022, the FDA approved sodium thiosulfate (Pedmark; Fennec Pharmaceuticals), an inorganic sodium salt, for risk reduction of hearing loss (ototoxicity) associated with cisplatin treatment in children aged ≥1 month to 18 years with nonmetastatic solid tumors. Sodium thiosulfate received an orphan drug designation for this indication.

The safety and efficacy of sodium thiosulfate when used after cisplatin infusions for ≥6 hours have not been determined; if hearing loss had already occurred, this drug may not reduce its risk after long cisplatin infusions.

This approval was based on the results of 2 phase 3 clinical trials: the multicenter, open-label, randomized controlled SIOPEL 6 and the Clinical Oncology Group (COG) ACCL0431. The SIOPEL 6 study included 114 pediatric patients with standard-risk hepatoblastoma who had received perioperative cisplatin-based chemotherapy. The main end point was the percentage of patients with Brock grade ≥1 hearing loss. The incidence of hearing loss was lower in the sodium thiosulfate plus cisplatin arm than in the cisplatin monotherapy arm (39% vs 68%, respectively; relative risk [RR], 0.58; 95% confidence interval [CI], 0.40-0.83).

The COG ACCL0431 study included 125 pediatric patients with solid tumors who received cumulative cisplatin doses of ≥200 mg/m2, with individual cisplatin doses infused over ≤6 hours. The incidence of hearing loss was lower in the sodium thiosulfate plus cisplatin arm than in the cisplatin monotherapy arm (44% vs 58%, respectively; RR, 0.75; 95% CI, 0.48-1.18).

The most common (≥25% with a between-arms difference of >5% vs cisplatin monotherapy) adverse reactions in both trials were vomiting, nausea, decreased hemoglobin, hypernatremia, and hypokalemia.

Related Items
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Online First published on September 8, 2023 in FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
JHOP - August 2023 Vol 13, No 4 published on August 17, 2023 in FDA Oncology Update
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
JHOP - August 2023 Vol 13, No 4 published on August 7, 2023 in FDA Oncology Update
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
JHOP - August 2023 Vol 13, No 4 published on August 4, 2023 in FDA Oncology Update
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
JHOP - August 2023 Vol 13, No 4 published on July 28, 2023 in FDA Oncology Update
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
JHOP - August 2023 Vol 13, No 4 published on June 30, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.